An Abbott (NYSE: ABT) official announced on social media that doctors completed the first commercial implant of Tendyne in the U.S.
Chris Waddell, Abbott’s U.S. VP for transcatheter aortic valve implantation (TAVI), posted the news on LinkedIn. It’s the latest milestone for Tendyne, a transcatheter mitral valve replacement (TMVR) system, after its FDA approval in May.
Dr. Frank Zidar, Dr. Faraz Kerendi, Dr. John Moscona and Dr. Stephen Dewan took part in the milestone procedure.
“All of us at Abbott are excited to share that the first U.S. commercial implantation of Tendyne, the only FDA-approved transcatheter mitral valve replacement system, was completed today at The Heart Hospital of Austin, Texas,” Waddell wrote. “Congratulations to [the doctors] as well as the entire Structural Team at Heart Hospital of Austin on completing this very significant milestone.”
Tendyne offers an option for patients with mitral valves that fail to function properly due to severe mitral annular calcification (MAC). MAC stiffens the annulus ring-like structure that supports the mitral valve. This can lead to mitral regurgitation or stenosis, disrupting the heart’s ability to effectively pump blood.
Some patients with severe MAC at high risk for open-heart surgery can’t have their valve repaired with Abbott’s MitraClip, according to a news release. For this population, Tendyne delivers an alternative, minimally invasive way to replace the leaky (mitral regurgitation) or narrowed (stenosis) valve.
(At DeviceTalks West Oct. 15-16, 2025, in Santa Clara, California, Abbott Neuromodulations’s Yagna Pathak, PhD, will sit on a panel exploring the clinical applications of connected health. Additionally, Abbott Vascular’s Chief Medical Officer, Dr. Ethan Korngold, will share how AI is shaping Abbott’s cardiovascular portfolio. Learn more and register at West.DeviceTalks.com.)
